Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.D., University of Cambridge (UK) 1993
  • Clinical Research Fellow, Clinical Pharmacology, Medicine, Addenbrooke's Hospital (Uk) 1984 - 1992
  • Senior Medical Training Rotations in General Medicine, Nephrology, Cardiology and ID, Addenbrooke's Hospital (Uk) 1984 - 1987
  • Junior Medical Training Rotations, Guys Hospital Medical School (London) 1981 - 1984
• Recognition
• 

  Awards & Honors

  • Fellowship . The Royal College of Physicians of London. 1998
• Publications & Artistic Works
• 

  Selected Publications

  • Journal Articles

    • Nunez, DJ, and D'Alessio, D. "Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors)." Diabetes, Obesity and Metabolism 20, no. 2 (February 2018): 233-237.  Full Text  Open Access Copy
    • Abbasi, A, Sahlqvist, A-S, Lotta, L, Brosnan, JM, Vollenweider, P, Giabbanelli, P, Nunez, DJ, Waterworth, D, Scott, RA, Langenberg, C, and Wareham, NJ. "A Systematic Review of Biomarkers and Risk of Incident Type 2 Diabetes: An Overview of Epidemiological, Prediction and Aetiological Research Literature." Edited by C Herder. PLOS ONE 11, no. 10 (October 27, 2016): e0163721-e0163721.  Full Text
    • Nunez, DJ, Yao, X, Lin, J, Walker, A, Zuo, P, Webster, L, Krug-Gourley, S, Zamek-Gliszczynski, MJ, Gillmor, DS, and Johnson, SL. "Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin." Diabetes, obesity & metabolism 18, no. 7 (July 2016): 654-662.  Full Text
    • Hodge, RJ, and Nunez, DJ. "Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?." Diabetes, Obesity and Metabolism 18, no. 5 (May 2016): 439-443.  Full Text
    • Hodge, RJ, Paulik, MA, Walker, A, Boucheron, JA, McMullen, SL, Gillmor, DS, and Nunez, DJ. "Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes." Edited by NC Barengo. PLOS ONE 11, no. 4 (April 19, 2016): e0153151-e0153151.  Full Text
    • Lin, J, Hodge, RJ, O'Connor-Semmes, RL, and Nunez, DJ. "GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects." Diabetes, Obesity and Metabolism 17, no. 10 (October 2015): 1007-1010.  Full Text
    • Vlasakakis, G, Johnson, SL, Lin, J, Yao, X, Gruenloh, CJ, Chism, JP, and Nunez, DJ. "Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers." Advances in Therapy 32, no. 7 (July 2015): 650-661.  Full Text
    • O’Connor-Semmes, RL, Lin, J, Hodge, RJ, Andrews, S, Chism, J, Choudhury, A, and Nunez, DJ. "GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety." Clinical Pharmacology & Therapeutics 96, no. 6 (December 2014): 704-712.  Full Text
    • Napolitano, A, Miller, S, Nicholls, AW, Baker, D, Van Horn, S, Thomas, E, Rajpal, D, Spivak, A, Brown, JR, and Nunez, DJ. "Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus." Edited by Z Zhu. PLoS ONE 9, no. 7 (July 2, 2014): e100778-e100778.  Full Text
    • Nunez, DJ, Bush, MA, Collins, DA, McMullen, SL, Gillmor, D, Apseloff, G, Atiee, G, Corsino, L, Morrow, L, and Feldman, PL. "Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies." Plos One 9, no. 4 (January 2014): e92494-null.  Full Text
    • Kapur, A, O’Connor-Semmes, R, Hussey, EK, Dobbins, RL, Tao, W, Hompesch, M, Smith, GA, Polli, JW, James Jr, CD, Mikoshiba, I, and Nunez, DJ. "First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus." BMC Pharmacology and Toxicology 14, no. 1 (December 2013).  Full Text
    • Hodge, RJ, Lin, J, Vasist Johnson, LS, Gould, EP, Bowers, GD, and Nunez, DJ. "Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes." Clinical Pharmacology in Drug Development 2, no. 3 (July 2013): 213-222.  Full Text
    • Mudaliar, S, Armstrong, DA, Mavian, AA, O'Connor-Semmes, R, Mydlow, PK, Ye, J, Hussey, EK, Nunez, DJ, Henry, RR, and Dobbins, RL. "Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes." Diabetes Care 35, no. 11 (November 1, 2012): 2198-2200.  Full Text
    • Wagner, JA, Prince, M, Wright, EC, Ennis, MM, Kochan, J, Nunez, DJR, Schneider, B, Wang, M-D, Chen, Y, Ghosh, S, Musser, BJ, and Vassileva, MT. "The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration." Clinical pharmacology and therapeutics 87, no. 5 (May 2010): 539-542. (Review)  Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.